Research archive for LLY

Vestact clients have been accumulating Eli Lilly shares, on our recommendation. Their weight-loss drug Zepbound will soon be supported by medical aids around the world. Slimmer people have much better health and longer life-expectancy, and go on paying their premiums. We expect that half of the world's adults will be on GLP-1 treatments in time.

Last week, Eli Lilly reported its latest numbers. The stock surged after the company improved its outlook for 2024, elevated by the potential for their new weight-loss drugs. The stock rose as much as 7.9% on the news, the most intraday gain since August, and has nearly doubled over the past 12 months.

Earlier this week, Eli Lilly said that their weight-loss drug Zepbound dramatically improved the symptoms of obstructive sleep apnea according to two late stage trials. This is very good news for the 20 million Americans who suffer from the condition, and for Eli Lilly shareholders.

We have written about Eli Lilly a lot lately because it has recently received the highly sort after Vestact stamp of approval. Most of the focus is on their weight-loss drug Zepbound which has only just hit the market. . Keep in mind that before all this excitement Eli Lilly was already a well-established player with a diversified portfolio of pharma brands.

The core of a Vestact portfolio is comprised of large, well-known multinationals like Apple, Microsoft, and Visa. We are always on the lookout for companies operating in future high-growth industries though. We call these our 'future hero' companies.

Pharma giant Eli Lilly had results out earlier this week. These are becoming highly anticipated by the market because of their fast-growing weight-loss drug Zepbound, along with the more established diabetes drug Mounjaro. Those drugs both have the same active ingredient.

Companies that make weight-loss drugs are attracting a lot of attention on Wall Street at the moment, and for good reason. Goldman Sachs estimates that these products will have sales of $100 billion by 2030.

Eli Lilly could be a useful addition to your New York portfolio. This drug company has a portfolio of existing blockbusters, and has treatments for weight-loss and Alzheimer's in its near-term pipeline.

In 2012, Novo Nordisk, a Danish pharmaceutical giant, developed a medication called semaglutide, designed to help manage type 2 diabetes. This injectable drug, later marketed as Ozempic, was approved by the FDA in 2017. Interestingly, while users reported various side effects, including nausea, some also experienced significant weight loss as an unintended consequence.

Food is great; don't you love eating? I do. As a species we evolved in scarcity. Who knew when you might get your next meal? That was fine when we were hunter-gatherers, but these days most of us spend all day sitting in an office chair, working on a computer screen.